http://publicationslist.org/data/alessio.amatu/atom.xml Alessio Amatuhttp://publicationslist.org/alessio.amatu$basepathfavicon.icoRecent additions to Alessio Amatu's PublicationsList.org pagehttp://publicationslist.org/publications.png2014-10-11T09:06:27Z http://publicationslist.org/alessio.amatu/refid18 2014-08-07T10:31:57Z

Regorafenib is an oral multikinase inhibitor that blocks the activity of protein kinases involved in the regulation of tumor angiogenesis (VEGFR1, 2, 3; angiopoietin-1 receptor), oncogenesis (stem cell growth factor receptor; RET; BRAF including BRAFV600E), and tumor microenvironment (PDGFR-β and FGFR). Based on data from the Phase III CORRECT study, regorafenib stands as a further option for pat...<br/><br/>Andrea Sartore-Bianchi, Annalisa Zeppellini, Alessio Amatu, Riccardo Ricotta, Katia Bencardino, Salvatore Siena (2014) <i>Expert review of anticancer therapy</i> <i></i> <i></i> 14: 3 255-265<br/>

http://publicationslist.org/alessio.amatu/refid19 2014-08-07T10:31:57Z

Colorectal cancers (CRCs) that are sensitive to the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab almost always develop resistance within several months of initiating therapy. We report the emergence of polyclonal KRAS, NRAS, and BRAF mutations in CRC cells with acquired resistance to EGFR blockade. Regardless of the genetic alterations, resistant cells consisten...<br/><br/>Sandra Misale, Sabrina Arena, Simona Lamba, Giulia Siravegna, Alice Lallo, Sebastijan Hobor, Mariangela Russo, Michela Buscarino, Luca Lazzari, Andrea Sartore-Bianchi, Katia Bencardino, Alessio Amatu, Calogero Lauricella, Emanuele Valtorta, Salvatore Siena, Federica Di Nicolantonio, Alberto Bardelli (2014) <i>Science translational medicine</i> <i></i> <i></i> 6: 224 <br/>

http://publicationslist.org/alessio.amatu/refid17 2014-08-07T10:31:57Z

Filippo Venturini, Valentina Gambi, Stefano Di Lernia, Angelo Vanzulli, Manuela Bramerio, Katia Bencardino, Alessio Amatu, Tiziana Cipani, Edoardo Forti, Emiliana Tarenzi, Andrea Sartore-Bianchi, Raffaele Pugliese, Salvatore Siena (2014) <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> <i></i> <i></i> : <br/>

http://publicationslist.org/alessio.amatu/refid21 2014-08-07T10:31:57Z

O(6)-methylguanine-DNA-methyltransferase (MGMT) is a DNA repair protein removing mutagenic and cytotoxic adducts from O(6)-guanine in DNA. Approximately 40% of colorectal cancers (CRC) display MGMT deficiency due to the promoter hypermethylation leading to silencing of the gene. Alkylating agents, such as dacarbazine, exert their antitumor activity by DNA methylation at the O(6)-guanine site, indu...<br/><br/>Alessio Amatu, Andrea Sartore-Bianchi, Catia Moutinho, Alessandro Belotti, Katia Bencardino, Giuseppe Chirico, Andrea Cassingena, Francesca Rusconi, Anna Esposito, Michele Nichelatti, Manel Esteller, Salvatore Siena (2013) <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> <i></i> <i></i> 19: 8 2265-2272<br/>

http://publicationslist.org/alessio.amatu/refid20 2014-08-07T10:31:57Z

EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases. We show that amplification of the MET proto-oncogene is associated with acquired resistance in tumors that do not develop KRAS mutations during anti-EGFR therap...<br/><br/>Alberto Bardelli, Simona Corso, Andrea Bertotti, Sebastijan Hobor, Emanuele Valtorta, Giulia Siravegna, Andrea Sartore-Bianchi, Elisa Scala, Andrea Cassingena, Davide Zecchin, Maria Apicella, Giorgia Migliardi, Francesco Galimi, Calogero Lauricella, Carlo Zanon, Timothy Perera, Silvio Veronese, Giorgio Corti, Alessio Amatu, Marcello Gambacorta, Luis A Diaz, Mark Sausen, Victor E Velculescu, Paolo Comoglio, Livio Trusolino, Federica Di Nicolantonio, Silvia Giordano, Salvatore Siena (2013) <i>Cancer discovery</i> <i></i> <i></i> 3: 6 658-673<br/>

http://publicationslist.org/alessio.amatu/refid22 2014-08-07T10:31:57Z

The purpose of this study was to assess the activity and safety of the combination of vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-negative (HER(-)) metastatic breast cancer (MBC).<br/><br/>Maria Rosa Strada, Raffaella Palumbo, Antonio Bernardo, Alberto Riccardi, Cristina Teragni, Guido Poggi, Mara Frascaroli, Alessio Amatu, Benedetta Montagna, Federico Sottotetti, Barbara Tagliaferri, Giovanni Bernardo (2012) <i>Clinical breast cancer</i> <i></i> <i></i> 12: 1 30-39<br/>

http://publicationslist.org/alessio.amatu/refid24 2014-08-07T10:31:57Z

Image-guided transcatheter hepatic chemoembolization (TACE) is accepted worldwide as an effective treatment for patients with unresectable hepatocellular carcinoma and liver metastases from neuroendocrine tumors, colorectal carcinomas, and uveal melanomas. Although the technique is relatively safe, it has been associated with several complications. We report the cases of two patients with colorect...<br/><br/>Guido Poggi, Pietro Quaretti, Benedetta Montagna, Federico Sottotetti, Barbara Tagliaferri, Emma Pozzi, Alessio Amatu, Chiara Pagella, Giovanni Bernardo (2011) <i>Cardiovascular and interventional radiology</i> <i></i> <i></i> 34 Suppl 2: S190-S194<br/>

http://publicationslist.org/alessio.amatu/refid23 2014-08-07T10:31:57Z

Metastatic colorectal cancer (mCRC) patients carrying KRAS mutated tumors do not benefit from epidermal growth factor receptor (EGFR)-targeted cetuximab- or panitumumab-based therapies. Indeed, the mutational status of KRAS is currently a validated predictive biomarker employed to select mCRC patients for EGFR targeted drugs. When patients fail standard 5-fluorouracil-, oxaliplatin-, irinotecan- a...<br/><br/>A Sartore-Bianchi, K Bencardino, A Cassingena, F Venturini, C Funaioli, T Cipani, A Amatu, L Pietrogiovanna, R Schiavo, F Di Nicolantonio, S Artale, A Bardelli, S Siena (2010) <i>Cancer treatment reviews</i> <i></i> <i></i> 36 Suppl 3: S1-S5<br/>

http://publicationslist.org/alessio.amatu/refid25 2014-08-07T10:31:57Z

The currently recommended treatment for patients infected with hepatitis C virus (HCV) is pegilated interferon alpha (IFN alpha) plus ribavirin. Despite the numerous benefits of this therapy, there is an increasing concern regarding his tolerance. Among the most common side effects, interferon may trigger the onset or exacerbation of autoimmune diseases. When chronic hepatitis C coexists with an a...<br/><br/>Guido Poggi, Laura Villani, Federico Sottotetti, Barbara Tagliaferri, Benedetta Montagna, Alessio Amatu, Giovanni Bernardo (2009) <i>Gastroenterology research and practice</i> <i></i> <i></i> 2009: <br/>

http://publicationslist.org/alessio.amatu/refid27 2014-08-07T10:31:57Z

Intrahepatic cholangiocarcinoma (ICC) is a rare life-threatening disease, whose only treatment with potential for cure is surgical resection. However, only 27% of patients at most are suitable for surgery when first diagnosed. For patients with unresectable disease, therapeutic options are chemotherapy or chemoradiation. We evaluated the feasibility and safety of oxaliplatin-eluting microspheres t...<br/><br/>Guido Poggi, A Amatu, B Montagna, P Quaretti, C Minoia, C Sottani, L Villani, B Tagliaferri, F Sottotetti, O Rossi, E Pozzi, F Zappoli, A Riccardi, G Bernardo (2009) <i>Cardiovascular and interventional radiology</i> <i></i> <i></i> 32: 6 1187-1192<br/>

http://publicationslist.org/alessio.amatu/refid26 2014-08-07T10:31:57Z

Drug Eluting Microsphere-Transarterial Chemoembolization (DEM-TACE) is a new delivery system to administrate drugs in a controlled manner useful for application in the chemoembolization of colorectal cancer metastases to the liver. DEM-TACE is focused to obtain higher concentrations of the drug to the tumor with lower systemic concentrations than traditional cancer chemotherapy. Therefore a specif...<br/><br/>Cristina Sottani, Emanuela Leoni, Benedetta Porro, Benedetta Montagna, Alessio Amatu, Federico Sottotetti, Pietro Quaretti, Guido Poggi, Claudio Minoia (2009) <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> <i></i> <i></i> 877: 29 3543-3548<br/>

http://publicationslist.org/alessio.amatu/refid31 2014-08-07T10:31:57Z

Guido Poggi, Alessio Amatu, Ilaria Palumbo, Giovanni Bernardo (2008) <i>Journal of vascular and interventional radiology : JVIR</i> <i></i> <i></i> 19: 4 625-626<br/>

http://publicationslist.org/alessio.amatu/refid30 2014-08-07T10:31:57Z

Malignant mesothelioma of the tunica vaginalis testis is a rare and aggressive asbestos-related malignancy that may pose difficult diagnostic problems. After 16 years of asbestos exposure, a 38-year-old petrochemical worker came to our notice with acute right testicular pain and swelling, simulating torsion of the spermatic cord. Histopathology of surgical samples of the tunica vaginalis revealed ...<br/><br/>Stefano M Candura, Andrea Canto, Alessio Amatu, Matteo Gerardini, Giorgio Stella, Mario Mensi, Guido Poggi (2008) <i>Anticancer research</i> <i></i> <i></i> 28: 2B 1365-1368<br/>

http://publicationslist.org/alessio.amatu/refid28 2014-08-07T10:31:57Z

While conventional transhepatic arterial chemoembolization (TACE) is accepted worldwide as an effective treatment for patients with unresectable hepatocellular carcinoma (HCC), its use in other hepatic tumors is not supported by randomized studies. Preliminary results have shown that new drug-eluting microspheres (DEM) seem to optimize TACE procedures. The aim of this study was to evaluate the cap...<br/><br/>Guido Poggi, Pietro Quaretti, Claudio Minoia, Giovanni Bernardo, Mario Regazzi Bonora, Raffaella Gaggeri, Anna Ronchi, Cesare Massa Saluzzo, Andrea Azzaretti, Giuseppe Rodolico, Michela Montagna, Alessio Amatu, Cristina Teragni, Ilaria Palumbo, Elena Traverso, Stefano Tonini, Laura Villani, Mario Scelsi, Paola Baiardi, Maria Grazia Felisi, Federico Sottotetti, Barbara Tagliaferri, Alberto Riccardi (2008) <i>Anticancer research</i> <i></i> <i></i> 28: 6B 3835-3842<br/>

http://publicationslist.org/alessio.amatu/refid29 2014-08-07T10:31:57Z

Intrahepatic cholangiocarcinoma account for 13% of annual cancer-related deaths worldwide and for 3% in the USA. Patient with unresectable disease can benefit from palliative therapies such as systemic chemotherapy. However, the only curative treatment for intrahepatic cholangiocarcinoma is complete surgical resection with histologically negative resection margins.<br/><br/>Guido Poggi, Pietro Quaretti, Claudio Minoia, Ilaria Palumbo, Laura Villani, Alessio Amatu, Cristina Teragni, Mario Scelsi, Federico Zappoli, Giovanni Bernardo (2008) <i>Anticancer research</i> <i></i> <i></i> 28: 5B 2987-2990<br/>

http://publicationslist.org/alessio.amatu/refid32 2014-08-07T10:31:57Z

Hepatocellular carcinoma is one of the most common malignancies in the world, with the liver being the second most frequently involved organ in metastatic disease. Although the gold standard treatment for malignant liver disease is surgical resection, only few patients can undergo such an intervention. This explains the current great interest in various loco-regional therapies, of which radiofrequ...<br/><br/>Guido Poggi, Alberto Riccardi, Pietro Quaretti, Cristina Teragni, Angelo Delmonte, Alessio Amatu, Gaia Saini, Mauro Mazzucco, Antonio Bernardo, Raffaella Palumbo, Andrea Canto, Simone Bernieri, Giovanni Bernardo (2007) <i>Anticancer research</i> <i></i> <i></i> 27: 4C 2911-2916<br/>